Statins in acute kidney injury: Friend or foe?

BMJ (Online)

Volumn 346, Issue 7900, 2013, Pages

  Fassett, Robert G ^a   Coombes, Jeff S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ACUTE KIDNEY FAILURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; DISEASE ASSOCIATION; DRUG POTENCY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER DYSFUNCTION; MYOPATHY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ACUTE KIDNEY INJURY; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE;

EID: 84875426687     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f1531     Document Type: Editorial

References (13)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
2. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93:154-8. (Pubitemid 38058722)
3. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:f880.
4. Collins GS, Altman DG. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK. Heart 2012;98:1091-7.
5. Roberts M. CRESTOR (Rosuvastatin calcium) NDA 21-366 JUPITER. 2009. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugadvisorycommittee/ucm194918.pdf.
6. Garcia Rodriguez LA, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Pharmacoepidemiol Drug Saf 2010;19:1218-24.
7. Molnar AO, Coca SG, Devereaux PJ, Jain AK, Kitchlu A, Luo J, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011;22:939-46.
8. Brunelli SM, Waikar SS, Bateman BT, Chang TI, Lii J, Garg AX, et al. Preoperative statin use and postoperative acute kidney injury. Am J Med 2012;125: 195-204,e3.
9. Argalious M, Xu M, Sun Z, Smedira N, Koch CG. Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery. Anesth Analg 2010;111:324-30.
10. Prowle JR, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Haase M, et al. Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery. Nephrology 2012;17:215-24.
11. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012;126:3008-16.
12. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 2012;7:e34450.
13. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-9. (Pubitemid 44294467)